Australia's most trusted
source of pharma news
Sunday, 05 October 2025
Posted 2 October 2025 AM
The second month of Spring ushered in six new PBS listings with Novartis scoring victory for two of its treatments.
Lucentis, for the treatment of proliferative diabetic retinopathy (PDR) without diabetic macular oedema will be available from this month. Health Minister Mark Butler said around 500 patients are expected to benefit from the listing, each saving more than $9000 for a year's treatment.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.